Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • robert.vince robert.vince Oct 9, 2012 9:07 AM Flag

    Seattle Genetics to receive milestone payments as Genentech advances two ADCs

    Seattle Genetics (SGEN) will receive undisclosed milestone payments under its antibody-drug conjugate collaboration with Genentech, a member of the Roche Group (RHHBY). The milestones were triggered by Genentech’s advancement of two ADCs utilizing Seattle Genetics technology into phase II clinical development. The phase II randomized, open-label study is designed to evaluate the safety and efficacy of ADCs anti-CD22 and DCDS4501A each in combination with Rituxan in patients with relapsed or refractory follicular non-Hodgkin lymphoma and relapsed or refractory diffuse large B-cell lymphoma.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SGEN
46.47-1.40(-2.92%)3:54 PMEDT